INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $290,000 | -4.0% | 13,378 | -21.8% | 0.00% | 0.0% |
| Q2 2018 | $302,000 | -16.1% | 17,114 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $360,000 | +13.6% | 17,114 | -21.9% | 0.00% | 0.0% |
| Q4 2017 | $317,000 | -6.8% | 21,905 | +1.6% | 0.00% | 0.0% |
| Q3 2017 | $340,000 | -0.6% | 21,566 | -21.7% | 0.00% | 0.0% |
| Q2 2017 | $342,000 | +4.9% | 27,551 | +37.4% | 0.00% | 0.0% |
| Q1 2017 | $326,000 | +7.6% | 20,048 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $303,000 | +40.3% | 20,048 | +261.0% | 0.00% | +100.0% |
| Q2 2016 | $216,000 | -37.8% | 5,554 | -14.0% | 0.00% | -50.0% |
| Q4 2015 | $347,000 | -1.4% | 6,455 | -26.5% | 0.00% | 0.0% |
| Q3 2015 | $352,000 | -16.2% | 8,779 | -33.3% | 0.00% | -33.3% |
| Q2 2015 | $420,000 | +59.7% | 13,158 | +19.4% | 0.00% | +50.0% |
| Q1 2015 | $263,000 | – | 11,023 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |